Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Launched by JOHNS HOPKINS UNIVERSITY · Oct 9, 2019

Keywords

ClinConnect Summary

This clinical trial is exploring whether psilocybin, a hallucinogenic substance, can help reduce depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease. The study aims to find out if psilocybin is safe to use in this group and whether it can improve their overall quality of life. Participants must be between 65 and 85 years old, have certain levels of cognitive function, and show signs of depression. They should also have a close friend or family member who can help with the study.

Those who take part can expect to receive psilocybin in a supportive environment, where their reactions and experiences will be closely monitored. The trial is currently recruiting participants, but there are specific health conditions that could exclude someone from joining, such as certain heart problems or a history of severe mental illness. If you're considering participation, it's a chance to contribute to important research that could help others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must meet either A) Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) criteria for Mild Neurocognitive Disorder due to AD or Major Neurocognitive Disorder due to AD with Mild severity (including probable), or B) meet criteria for MCI including a subjective memory complaint relative to previous functioning and confirmed by Clinical Dementia Rating (CDR) Memory score at screening of \>0.5
• • Have Mini-Mental State Examination scores \>18
• • Have a Montreal Cognitive Assessment score \<26.
• • Have Cornell Scale for Depression in Dementia (CSDD) patient score \>/= 6, or Geriatric Depression Scale-Short Form score ≥ 5, indicating at minimum a mild to moderate degree of distress.
• • Acetylcholinesterase inhibitors are allowed so long as the dose has been stable for \> 6 weeks.
• • Concurrent pharmacotherapy with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI), and/or bupropion is allowed if the type and frequency of the therapy has been stable for at least two months prior to screening. Allowable bupropion doses for participants will be ≤300mg/day.
• • Have a close friend or family member willing and able to serve the role of community observer / informant for data collection procedures
• Exclusion Criteria:
• • Individuals 86 years of age or older will be excluded.
• • Currently taking antipsychotics, monoamine oxidase (MAO) inhibitors, or antidepressant medications other than SSRIs, SNRIs, or bupropion. Allowable bupropion doses for participants will be ≤300mg/day.
• • Long-acting opioid pain medications (e.g. oxycodone sustained release, morphine sustained release - which are usually taken at 12 hour intervals) will be allowed if the last dose occurred at least 2 hours before psilocybin administration and the next dose was not scheduled until at least 8 hours after psilocybin administration.
• • Participants must agree not to take sildenafil, tadalafil, or similar medications within 72 hours of each psilocybin administration, as these medications may potentiate hypotensive reactions to psilocybin
• • Cardiovascular conditions: angina, a clinically significant ECG abnormality (e.g. atrial fibrillation or heart-rate corrected QT interval (QTc) \>450msec), Transient Ischemic Attack (TIA) in the last 6 months, stroke, artificial heart valves, or uncontrolled hypertension with resting blood pressure systolic \>150 or diastolic \>95
• • Minimum acceptable heartrate at screening is 50 bpm unless the individual is cleared for participation by a cardiologist, in accord with the American College of Cardiology's 2018 guidelines for bradycardia
• • Seizure disorder
• • Insulin dependent diabetes mellitus
• • Renal disease (creatinine clearance \< 40 ml/min using the Cockcroft and Gault equation)
• • Baseline liver enzyme elevation \>2x the upper limit of normal
• • Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I Disorder
• • Family (i.e., 1st degree relative) history of Schizophrenia, Psychotic Disorder (unless substance-induced or due to a medical condition), or Bipolar I Disorder
• • Past-year hallucinogen use.